Osteoporosis Therapies: Evidence from Health-Care Databases and Observational Population Studies
Open Access
- 20 August 2010
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 87 (5) , 375-384
Abstract
Osteoporosis is a well-recognized disease with severe consequences if left untreated. Randomized controlled trials are the most rigorous method for determining the efficacy and safety of therapies. Nevertheless, randomized controlled trials underrepresent the real-world patient population and are costly in both time and money. Modern technology has enabled researchers to use information gathered from large health-care or medical-claims databases to assess the practical utilization of available therapies in appropriate patients. Observational database studies lack randomization but, if carefully designed and successfully completed, can provide valuable information that complements results obtained from randomized controlled trials and extends our knowledge to real-world clinical patients. Randomized controlled trials comparing fracture outcomes among osteoporosis therapies are difficult to perform. In this regard, large observational database studies could be useful in identifying clinically important differences among therapeutic options. Database studies can also provide important information with regard to osteoporosis prevalence, health economics, and compliance and persistence with treatment. This article describes the strengths and limitations of both randomized controlled trials and observational database studies, discusses considerations for observational study design, and reviews a wealth of information generated by database studies in the field of osteoporosis.Keywords
This publication has 62 references indexed in Scilit:
- Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesOsteoporosis International, 2009
- Adherence to monthly and weekly oral bisphosphonates in women with osteoporosisOsteoporosis International, 2009
- RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reductionOsteoporosis International, 2008
- Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ, 2008
- Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025Journal of Bone and Mineral Research, 2007
- Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort studyOsteoporosis International, 2006
- Does Random Treatment Assignment Cause Harm to Research Participants?PLOS Medicine, 2006
- Addressing the issue of channeling bias in observational studies with propensity scores analysisResearch in Social and Administrative Pharmacy, 2006
- Comparative Safety of Atorvastatin 80 mg Versus 10 mg Derived from Analysis of 49 Completed Trials in 14,236 PatientsThe American Journal of Cardiology, 2006
- Costs and quality of life associated with osteoporosis-related fractures in SwedenOsteoporosis International, 2005